{"filing":{"accession_number":"0001213900-26-078874","cik":"0001944552","ticker":"ANL","company_name":"Adlai Nortye Ltd.","form":"6-K","filing_date":"2026-07-16","report_date":null,"primary_document":"ea0298278-6k_adlai.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1944552/000121390026078874/ea0298278-6k_adlai.htm"},"events":[{"id":18538,"run_id":16664,"accession_number":"0001213900-26-078874","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces a clinical development milestone: the first patient dosed in the intermittent weekly dosing arm of a Phase 1 trial for AN9025, a pan-RAS(ON) inhibitor. While the company is clinical-stage and this represents progress in its lead therapeutic candidate, the disclosure is a clinical milestone rather than a discrete material event (M\u0026A, restatement, executive change, etc.). The announcement is material to investors assessing the company's pipeline advancement and clinical strategy, but does not fit the specific event-type taxonomy; it is an operational/strategic milestone in drug development.","company_name":"Adlai Nortye Ltd.","ticker":"ANL","filing_date":"2026-07-16","form":"6-K","submitted_at":null,"items":[{"id":17372,"accession_number":"0001213900-26-078874","item_number":"EX-99.1","item_title":"ea029827801ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a clinical development milestone: the first patient dosed in the intermittent weekly dosing arm of a Phase 1 trial for AN9025, a pan-RAS(ON) inhibitor. While the company is clinical-stage and this represents progress in its lead therapeutic candidate, the disclosure is a clinical milestone rather than a discrete material event (M\u0026A, restatement, executive change, etc.). The announcement is material to investors assessing the company's pipeline advancement and clinical strategy, but does not fit the specific event-type taxonomy; it is an operational/strategic milestone in drug development.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-17T10:04:23.481748+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17372,"accession_number":"0001213900-26-078874","item_number":"EX-99.1","item_title":"ea029827801ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a clinical development milestone: the first patient dosed in the intermittent weekly dosing arm of a Phase 1 trial for AN9025, a pan-RAS(ON) inhibitor. While the company is clinical-stage and this represents progress in its lead therapeutic candidate, the disclosure is a clinical milestone rather than a discrete material event (M\u0026A, restatement, executive change, etc.). The announcement is material to investors assessing the company's pipeline advancement and clinical strategy, but does not fit the specific event-type taxonomy; it is an operational/strategic milestone in drug development.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-17T10:04:23.481748+00:00","company_name":"Adlai Nortye Ltd.","ticker":"ANL","filing_date":"2026-07-16"}]}